BC Innovations | Jul 11, 2018
Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
BC Innovations | Jun 13, 2018
Distillery Therapeutics

Cancer

INDICATION: Solid tumors; pancreatic cancer; colorectal cancer; breast cancer; lung cancer; ovarian cancer Patient sample and mouse studies suggest anti-ANTXR1 antibody-drug conjugates (ADCs) could help treat solid tumors. In tissue samples from esophageal, kidney, uterine,...
BC Innovations | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting ANTXR1 could help treat triple-negative breast cancer (TNBC). In patient samples, levels of ANTXR1 were higher in...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Anthrax toxin receptor 1 (ANTXR1; TEM8) Studies in mice suggest inhibiting TEM8 could help treat cancer. In multiple mouse models of cancer, injection of...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
BC Innovations | Mar 8, 2012
Targets & Mechanisms

A TEM to kill

Novartis AG and the National Cancer Institute have developed mAbs against anthrax toxin receptor 1 that inhibit tumor angiogenesis in multiple mouse models of cancer with fewer side effects than anti-VEGF therapies. 1 A key...
Items per page:
1 - 6 of 6